Lexaria Bioscience Corp.
LEXX · NASDAQ
8/31/2025 | 8/31/2024 | 8/31/2023 | 8/31/2022 | |
|---|---|---|---|---|
| Market Cap | – | $48 | $7 | $17 |
| - Cash | $2 | $6 | $1 | $6 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $42 | $6 | $12 |
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 52% | 105.2% | -11.4% | – |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 99.6% | 99% | 86.1% | 71.9% |
| EBITDA | -$12 | -$6 | -$6 | -$7 |
| % Margin | -1,683% | -1,222.8% | -2,824.2% | -2,551.4% |
| Net Income | -$12 | -$6 | -$7 | -$7 |
| % Margin | -1,686% | -1,248.2% | -2,946.4% | -2,846.3% |
| EPS Diluted | -0.66 | -0.47 | -1.01 | -1.24 |
| % Growth | -40.4% | 53.5% | 18.5% | – |
| Operating Cash Flow | -$10 | -$5 | -$6 | -$5 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$10 | -$5 | -$6 | -$5 |